|
December 7, 2016
|
Highlights from ASH |
|
As development of molecular biomarkers hastens, some big challenges are arising. Read more. |
|
Immune checkpoint inhibitors are taking the stage in treating relapsed and refractory Hodgkin lymphoma. Read more. |
|
Numerous treatment options for multiple myeloma exist, but how best to sequence them is still a challenge. Read more. |
Top content
Treatment advances and promising signs for the future. Read more. |
|
|
We welcome your feedback!
Please send your comments to:
Aubrey Westgate
Executive Editor
Managed Healthcare Executive
[email protected] |
DISCLAIMER:
This information has been independently developed and provided by the editors of Managed Healthcare Executive. The sponsors do not endorse and are not responsible for the accuracy of the content or for practices or standards of non-sponsor sources. These articles may discuss regimens that have not been approved by the FDA. For full prescribing information including indications, contraindications, warnings, precautions, and adverse experiences, please see the appropriate manufacturer's product circular. |
|
